The content is available as a PDF (563.2 KB).
References
- 1.Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J, Boyd M (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83: 757–766 [DOI] [PubMed] [Google Scholar]
- 2.Boyd MR, Paull KD, Rubinstein LR (1992) In cytotoxic anticancer drugs: Models and concepts for drug discovery and development. In: Datadisplay and analysis strategies for the NCI disease orientedin vitro antitumor drug screen, edited by Valeriote FA, Corbett TH, Baker LH, Kluwer Academic Publishers, Boston, pp 11–34 [Google Scholar]
- 3.Paull KD, Hamel E, Malspeis L (1993) Prediction of biochemical mechanisms of action from the in vitro antitumor screen of the National Cancer Institute. In: Cancer Chemotherapeutic Agents, edited by Foye WE, American Chemical Society, Washington, D. C. [Google Scholar]
- 4.Paull KD, Lin CM, Malspeis L, Hamel E (1992) Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Res 52: 3892–3900 [PubMed] [Google Scholar]
- 5.Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81: 1088–1092 [DOI] [PubMed] [Google Scholar]
- 6.Weinstein JN, Kohn KW, Grever MR, Viswanadhan VN, Rubinstein LV, Monks A, Scudiero DA, Welch L, Koutsoukos A, Chiausa AJ, Paull KD (1992) Neural computing in cancer drug development: Predicting mechanism of action. Science 258: 447–451 [DOI] [PubMed] [Google Scholar]
- 7.Weinstein JN, Myers T, Buolamwini J, Raghavan K, Viswanadhan VN, Licht J, Rubinstein LV, Koutsoukos AD, Kohn KW, Zaharevitz D, Grever MR, Monks A, Scudiero DA, Chabner BA, Anderson NL, Paull KD (1994) Predictive statistics and artificial intelligence in the U. S. National Cancer Institute's drug discovery program for cancer and AIDS. Stem Cells 12: 13–22 [DOI] [PubMed] [Google Scholar]
- 8.Chabner BA, Weinstein JN, Paull KD, Grever MR (1994) Cell line-based screening for new anticancer drug. In: Banzet P, Holland JF, Khayat D, and Weil M (Eds.) Cancer Treatment, an Update. Paris: Springer-Verlag France, pp. 10–16 [Google Scholar]
- 9.Van Osdol W, Myers TG, Paull KD, Kohn KW, Weinstein JN (1994) Use of the Kohonen self-organizing map to study the mechanisms of action of chemotherapeutic agents. J Natl Cancer Inst 86: 1853–1859 [DOI] [PubMed] [Google Scholar]
- 10.Koutsoukos AD, Rubinstein LV, Faraggi D, Kalyandrug S, Weinstein JN, Paul KD, Kohn KW, Simon RM (1994) Discrimination techniques applied to the NCl in vitro antitumor drug screen: Predicting biochemical mechanism of action. Statistics in Medicine 13: 719–730 [DOI] [PubMed] [Google Scholar]
- 11.Keating MJ, McCredie KB, Benjamin RS, Bodey GP, Zander A, Smith TL, Freireich EJ (1981) Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine, and prednisone (ROAP). Blood 58: 584–591 [PubMed] [Google Scholar]
- 12.Morrison FS, Benjamin R, Amare M, Costanzi JJ, Hussein K, Ryan DH, Balcerzak S, Pendleton OJ (1982) Rubidazone in combination with Ara-C, vincristine and prednisone (ROAP) in the treatment of adult acute leukemia. Am J Clin Oncol 5: 645–648 [DOI] [PubMed] [Google Scholar]
- 13.Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B, Beran M, McCredie KB, Freireich EJ (1989) Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 7: 1071–1080 [DOI] [PubMed] [Google Scholar]
- 14.Bickers J, Benjamin R, Wilson H, Eyre H, Hewlett J, McCredie K (1981) Rubidazone in adults with previously treated acute leukemia and blast cell phase of chronic myelocytic leukemia: A Southwest Oncology Group study. Cancer Treat Rep 65: 427–430 [PubMed] [Google Scholar]
- 15.Keating MJ, Smith TL, McCredie KB, Bodey GP, Hersh EM, Gutterman JU, Gehan E, Freireich EJ (1981) A four-year experience with anthracycline, cytosine arabinoside, vincristine, and prednisone combination chemotherapy in 325 adults with acute leukemia. Cancer 47: 2779–2788 [DOI] [PubMed] [Google Scholar]
- 16.Walters RS, Kantarjian HM, Keating MJ, Estey EH, McCredie KB, Freireich EJ (1987) Intensive treatment of acute leukemia in adults 70 years of age and older. Cancer 60: 149–155 [DOI] [PubMed] [Google Scholar]
- 17.Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, Grever M, Bates S, Fojo T (1995) Generation of a Drug Resistance Profile by Quantitation ofmdr-1/P-glycoprotein in the cell lines of the National Cancer Institute anticancer drug screen. J Clin Investigations 95: 2205–2214 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Lee JS, Paull K, Alvarez M, Hose C, Monks A, Grever M, Fojo AT Bates SE (1994) Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Molec Pharmacol 46: 627–638 [PubMed] [Google Scholar]
- 19.Zhang XP, Ritke MK, Yalowich JC, Slovak ML, Ho JP, Collins KI, Anable T, Arceci RJ, Durr FE, Greenberger LM (1994) P-glycoprotein mediates profound resistance to bisantrene. Oncol Res 6: 291–301 [PubMed] [Google Scholar]
- 20.Utsugi S, Demuth S, Hanna N (1989) Synergistic antitumor effects of topoisomerase inhibitors and natural cell-mediated cytotoxicity. Cancer Res 49: 1429–1433 [PubMed] [Google Scholar]